| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439398 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
CABA rechallenge may be a treatment option without cumulative toxicity in heavily pretreated patients with mCRPC who are still fit and had a progression >3 months after the last CABA injections.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Constance Thibault, Jean-Christophe Eymard, Alison Birtle, Michael Krainer, Giulia Baciarello, Aude Fléchon, Sylvestre Le Moulec, Dominique Spaeth, Brigitte Laguerre, Orazio Caffo, Jean-Laurent Deville, Phillipe Beuzeboc, Ali Hasbini,